Serge Korjian

3.5k total citations · 1 hit paper
68 papers, 2.2k citations indexed

About

Serge Korjian is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Serge Korjian has authored 68 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Cardiology and Cardiovascular Medicine, 22 papers in Surgery and 18 papers in Internal Medicine. Recurrent topics in Serge Korjian's work include Atrial Fibrillation Management and Outcomes (20 papers), Venous Thromboembolism Diagnosis and Management (18 papers) and Antiplatelet Therapy and Cardiovascular Diseases (17 papers). Serge Korjian is often cited by papers focused on Atrial Fibrillation Management and Outcomes (20 papers), Venous Thromboembolism Diagnosis and Management (18 papers) and Antiplatelet Therapy and Cardiovascular Diseases (17 papers). Serge Korjian collaborates with scholars based in United States, United Kingdom and Canada. Serge Korjian's co-authors include Yazan Daaboul, C. Michael Gibson, Roxana Mehran, Christoph Bode, Gregory Y.H. Lip, Paul Burton, Freek W.A. Verheugt, Marc Cohen, Keith A.A. Fox and Martin van Eickels and has published in prestigious journals such as New England Journal of Medicine, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Serge Korjian

67 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI

2016 942 citations C. Michael Gibson, Roxana Mehran et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Serge Korjian United States	20	1.5k	692	566	204	137	68	2.2k
Yazan Daaboul United States	16	1.4k 0.9×	644 0.9×	454 0.8×	138 0.7×	123 0.9×	51	2.0k
Antonio Tello‐Montoliu Spain	21	1.0k 0.7×	310 0.4×	477 0.8×	172 0.8×	126 0.9×	74	1.6k
Alon Schaffer Italy	25	950 0.6×	255 0.4×	537 0.9×	210 1.0×	189 1.4×	80	1.8k
Anthony J. Dalby United States	19	2.2k 1.4×	511 0.7×	1.1k 1.9×	295 1.4×	117 0.9×	34	2.6k
Monica Verdoia Italy	27	1.7k 1.1×	419 0.6×	1.0k 1.8×	271 1.3×	291 2.1×	190	3.0k
Ernesto Paolasso Argentina	17	1.5k 1.0×	329 0.5×	469 0.8×	300 1.5×	177 1.3×	19	2.0k
Marcel A. van de Ree Netherlands	19	488 0.3×	469 0.7×	499 0.9×	265 1.3×	214 1.6×	38	1.3k
Mattía Galli Italy	22	1.4k 0.9×	296 0.4×	689 1.2×	149 0.7×	74 0.5×	138	1.9k
Rolf P. Kreutz United States	16	984 0.6×	403 0.6×	482 0.9×	132 0.6×	99 0.7×	54	1.4k
Lucia Barbieri Italy	23	880 0.6×	225 0.3×	502 0.9×	157 0.8×	194 1.4×	114	1.6k

Countries citing papers authored by Serge Korjian

Since Specialization

Citations

This map shows the geographic impact of Serge Korjian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serge Korjian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serge Korjian more than expected).

Fields of papers citing papers by Serge Korjian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Serge Korjian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serge Korjian. The network helps show where Serge Korjian may publish in the future.

Co-authorship network of co-authors of Serge Korjian

This figure shows the co-authorship network connecting the top 25 collaborators of Serge Korjian. A scholar is included among the top collaborators of Serge Korjian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Serge Korjian. Serge Korjian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Korjian, Serge, George S. Chrysant, & Suzanne J. Baron. (2025). Acoustic-based systems for the evaluation of coronary artery disease: A systematic literature review. Cardiovascular revascularization medicine. 81. 137–143.

Januzzi, James L., Alka Shaunik, Maria Cecilia Bahit, et al.. (2024). Barriers and Facilitators to Implementation of Intravenous Cardiovascular Treatments in Ambulatory Settings. ESC Heart Failure. 12(1). 695–700. 1 indexed citations

Baron, Suzanne J., Sourbha S. Dani, Serge Korjian, Matthew R. Reynolds, & C. Michael Gibson. (2024). COST-EFFECTIVENESS OF THE CADSCOR SYSTEM IN LOW RISK PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT WITH CHEST PAIN. Journal of the American College of Cardiology. 83(13). 1300–1300. 1 indexed citations

Korjian, Serge, Killian J. McCarthy, Donald E. Cutlip, et al.. (2024). Drug-Coated Balloons in the Management of Coronary Artery Disease. Circulation Cardiovascular Interventions. 17(5). e013302–e013302. 14 indexed citations

Korjian, Serge, Gerald Chi, Arzu Kalaycı, et al.. (2023). Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction. European Heart Journal - Cardiovascular Pharmacotherapy. 9(4). 387–398. 15 indexed citations

Bahit, M. Cecilia, Serge Korjian, Yazan Daaboul, et al.. (2023). Patient Adherence to Secondary Prevention Therapies After an Acute Coronary Syndrome: A Scoping Review. Clinical Therapeutics. 45(11). 1119–1126. 11 indexed citations

Korjian, Serge, et al.. (2023). Entrapment of high-density grid mapping catheter in a percutaneous ventricular assist device pigtail during ventricular tachycardia ablation with percutaneous hemodynamic support. HeartRhythm Case Reports. 9(7). 478–481. 1 indexed citations

Kalaycı, Arzu, C. Michael Gibson, Paul M. Ridker, et al.. (2022). ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future. Current Atherosclerosis Reports. 24(7). 585–597. 22 indexed citations

Zheng, Bo, Shinya Goto, Regina Clementi, et al.. (2022). Effect of CSL112 (apolipoprotein A‐I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross‐study comparison. Clinical and Translational Science. 15(10). 2331–2341. 5 indexed citations

10.

Chi, Gerald, Jane Lee, Clara Fitzgerald, et al.. (2021). EARLY AND LATE RECURRENT CARDIOVASCULAR RISK IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROME - META-ANALYSIS AND IMPLICATIONS IN TRIAL DESIGN. Journal of the American College of Cardiology. 77(18). 137–137. 1 indexed citations

11.

Lee, Jane, Gerald Chi, Clara Fitzgerald, et al.. (2021). ASSOCIATION OF CHOLESTEROL EFFLUX CAPACITY WITH ADVERSE CARDIOVASCULAR OUTCOMES - A META-ANALYSIS. Journal of the American College of Cardiology. 77(18). 1486–1486. 1 indexed citations

12.

Korjian, Serge, Yazan Daaboul, François Laliberté, et al.. (2018). Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). The American Journal of Cardiology. 123(3). 355–360. 4 indexed citations

13.

Chi, Gerald, Tarek Nafee, Samuel Z. Goldhaber, et al.. (2017). Abstract 20322: Extended-Duration Betrixaban Reduces the Risk of Venous Thromboembolism-Related Rehospitalization Among Acutely Ill Hospitalized Medical Patients: An APEX Trial Substudy. Circulation. 1 indexed citations

14.

Yee, Megan K., Tarek Nafee, Yazan Daaboul, et al.. (2017). Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. Journal of Thrombosis and Thrombolysis. 45(1). 1–8. 10 indexed citations

15.

Nafee, Tarek, Aysha Aslam, Gerald Chi, et al.. (2017). Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. Expert Review of Cardiovascular Therapy. 15(4). 237–245. 7 indexed citations

16.

Gibson, C. Michael, Tarek Nafee, Samuel Z. Goldhaber, et al.. (2017). Abstract 20393: Full-Dose Betrixaban Reduces Venous Thromboembolism-Related Mortality: An APEX Trial Substudy. Circulation. 2 indexed citations

17.

Gibson, C. Michael, Serge Korjian, Gerald Chi, et al.. (2017). Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. Journal of the American Heart Association. 6(7). 34 indexed citations

18.

Gibson, C. Michael, Duane S. Pinto, Gerald Chi, et al.. (2016). Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation. 135(4). 323–333. 64 indexed citations

19.

Daaboul, Yazan, et al.. (2016). Medical education in a foreign language and history-taking in the native language in Lebanon – a nationwide survey. BMC Medical Education. 16(1). 298–298. 24 indexed citations

20.

Gibson, C. Michael, Serge Korjian, Pierluigi Tricoci, et al.. (2016). Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. American Heart Journal. 180. 22–28. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact